Cargando…

Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

BACKGROUND: For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3–4 adverse events in a large number of patients. Peptide Receptor Radionuclide Therapy (PRRT), which has also been suggested to be a useful treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beukhof, Carolien M., Brabander, Tessa, van Nederveen, Francien H., van Velthuysen, Marie-Louise F., de Rijke, Yolanda B., Hofland, Leo J., Franssen, Gaston J. H., Fröberg, Lideke A. C., Kam, Boen L. R., Visser, W. Edward, de Herder, Wouter W., Peeters, Robin P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451300/ https://www.ncbi.nlm.nih.gov/pubmed/30953466 http://dx.doi.org/10.1186/s12885-019-5540-5

Ejemplares similares

Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
por: Minczeles, N.S., et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours
por: Blažević, Anela, et al.
Publicado: (2021)

Radionuclide therapy in the time of COVID-19
por: Brabander, Tessa, et al.
Publicado: (2020)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
por: da Silva, Tiago Nunes, et al.
Publicado: (2018)

A Clinical Guide to Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATATE in Neuroendocrine Tumor Patients
por: Becx, Morticia N., et al.
Publicado: (2022)

Salvage peptide receptor radionuclide therapy with [(177)Lu-DOTA,Tyr(3)]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
por: van der Zwan, W. A., et al.
Publicado: (2018)

Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome
por: Zandee, Wouter T, et al.
Publicado: (2021)

Serum microRNA profiles in athyroid patients on and off levothyroxine therapy
por: Massolt, Elske T., et al.
Publicado: (2018)

Selenium Status Is Positively Associated with Bone Mineral Density in Healthy Aging European Men
por: Beukhof, Carolien M., et al.
Publicado: (2016)

Aberrant tryptophan metabolism in stromal cells is associated with mesenteric fibrosis in small intestinal neuroendocrine tumors
por: Blažević, Anela, et al.
Publicado: (2022)

Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: de Keizer, Bart, et al.
Publicado: (2008)

Conus Medullaris Syndrome following Radionuclide Cisternography
por: Choi, Jay Chol
Publicado: (2014)

Induction therapy with (177)Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients
por: Minczeles, Noémie S., et al.
Publicado: (2022)

Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women
por: Blažević, Anela, et al.
Publicado: (2022)

ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase
por: Hofland, Johannes, et al.
Publicado: (2013)

MON-549 How Does the 2015 American Thyroid Association Risk Stratification System Perform in High Risk Thyroid Cancer Patients?
por: van Velsen, Evert, et al.
Publicado: (2019)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy
por: Grossrubatscher, Erika, et al.
Publicado: (2020)

Comparison of [(18)F]DOPA and [(68)Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
por: Veenstra, Emile B., et al.
Publicado: (2022)

Effect of epigenetic treatment on SST(2) expression in neuroendocrine tumour patients
por: Refardt, Julie, et al.
Publicado: (2022)

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
por: Fröberg, Alida C., et al.
Publicado: (2009)

Epigenetic regulation of SST(2) expression in small intestinal neuroendocrine tumors
por: Klomp, Maria J., et al.
Publicado: (2023)

Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)

Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy
por: Ebbers, Sander C., et al.
Publicado: (2022)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Radionuclide Imaging of Apoptosis in Malignancies: Promise and Pitfalls of (99m)Tc-Hynic-rh-Annexin V Imaging
por: Kartachova, M.S., et al.
Publicado: (2008)

Evaluation of the 2015 ATA Guidelines in Patients With Distant Metastatic Differentiated Thyroid Cancer
por: van Velsen, Evert F S, et al.
Publicado: (2019)

Report on short-term side effects of treatments with (177)Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours
por: van Essen, Martijn, et al.
Publicado: (2008)

Pressure‐volume analysis in athyroid patients off and on thyroxine supplementation: a pilot study
por: Bastos, Marcelo B., et al.
Publicado: (2018)

Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives
por: Herrera-Martínez, Aura D., et al.
Publicado: (2018)

Recurrent intramedullary endometriosis of the conus medullaris: A case report of diagnostic pitfalls and a review of literature
por: Gomez, Deshan, et al.
Publicado: (2023)

Dosimetric evaluation of radionuclides for VCAM-1-targeted radionuclide therapy of early brain metastases
por: Falzone, Nadia, et al.
Publicado: (2018)

Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
por: Hofland, Johannes, et al.
Publicado: (2020)

Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results
por: Schoffelen, R, et al.
Publicado: (2013)

Adrenal Medullary Hyperplasia Is a Precursor Lesion for Pheochromocytoma in MEN2 Syndrome()()
por: Korpershoek, Esther, et al.
Publicado: (2014)

Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study
por: Campana, Claudia, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
por: Bodei, Lisa, et al.
Publicado: (2020)

Malignant Struma Ovarii: Good Response after Thyroidectomy and (131)I Ablation Therapy
por: Janszen, Erica W.M., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_1b52i37vo60s1ovbn7bltf9ko1